What is HC Wainwright's Estimate for Insmed FY2025 Earnings?

Insmed Incorporated (NASDAQ:INSM - Free Report) - Equities research analysts at HC Wainwright upped their FY2025 earnings per share estimates for Insmed in a note issued to investors on Wednesday, June 11th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical company will earn ($5.05) per share for the year, up from their previous estimate of ($5.06). HC Wainwright has a "Buy" rating and a $120.00 price target on the stock. The consensus estimate for Insmed's current full-year earnings is ($4.56) per share. HC Wainwright also issued estimates for Insmed's FY2026 earnings at ($2.52) EPS, FY2027 earnings at $0.38 EPS and FY2029 earnings at $5.21 EPS.

A number of other equities research analysts have also commented on the stock. Truist Financial upped their price objective on shares of Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Cantor Fitzgerald reiterated an "overweight" rating on shares of Insmed in a report on Wednesday, February 19th. Guggenheim reaffirmed a "buy" rating and issued a $101.00 target price on shares of Insmed in a report on Tuesday, February 25th. Citigroup upgraded Insmed to a "buy" rating in a research note on Tuesday. Finally, Jefferies Financial Group reissued a "buy" rating on shares of Insmed in a research report on Tuesday. One investment analyst has rated the stock with a sell rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $104.81.

Insmed Trading Up 1.9%

Shares of Insmed stock traded up $1.85 on Friday, hitting $98.73. The stock had a trading volume of 5,318,455 shares, compared to its average volume of 2,168,826. Insmed has a twelve month low of $60.40 and a twelve month high of $100.00. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The firm has a market capitalization of $17.98 billion, a P/E ratio of -17.66 and a beta of 0.80. The stock has a 50 day moving average of $70.73 and a 200 day moving average of $73.47.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The business had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Insmed's revenue for the quarter was up 22.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.06) EPS.

Institutional Investors Weigh In On Insmed

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Insmed by 3.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,401 shares of the biopharmaceutical company's stock valued at $446,000 after buying an additional 186 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Insmed by 8.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 423,094 shares of the biopharmaceutical company's stock worth $29,590,000 after purchasing an additional 32,960 shares in the last quarter. Values First Advisors Inc. increased its position in Insmed by 4.4% during the 4th quarter. Values First Advisors Inc. now owns 5,199 shares of the biopharmaceutical company's stock worth $359,000 after purchasing an additional 221 shares in the last quarter. V Square Quantitative Management LLC grew its holdings in shares of Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 248 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in Insmed by 9.6% in the fourth quarter. Rhumbline Advisers now owns 288,337 shares of the biopharmaceutical company's stock valued at $19,907,000 after purchasing an additional 25,292 shares during the last quarter.

Insiders Place Their Bets

In other Insmed news, CEO William Lewis sold 6,830 shares of the business's stock in a transaction on Tuesday, April 15th. The shares were sold at an average price of $70.16, for a total value of $479,192.80. Following the completion of the transaction, the chief executive officer now owns 233,924 shares in the company, valued at $16,412,107.84. The trade was a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Sara Bonstein sold 57,766 shares of the company's stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $89.12, for a total value of $5,148,105.92. Following the transaction, the chief financial officer now directly owns 103,412 shares of the company's stock, valued at approximately $9,216,077.44. This represents a 35.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 319,932 shares of company stock valued at $25,733,693. Insiders own 3.00% of the company's stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.